Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.5452W HIGH $40.23
Volume
8.99 K
Value Traded
65.19 K
Short % Float
-
+3.19%Week
-11.9%1 Month
-20.68%3 Month
-43.94%6 Month
+21.8%5 Year
+21.8%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.44 B
EPS (TTM)
-1.94
P/E Ratio
-
Ent. Value
1.90 B
Total Shares
93.39 M
Float Shares
-
Insiders
-
Institutions
0.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AAPG Catalyst Timeline
Dated clinical, regulatory and corporate events for Ascentage Pharma Group International - American Depository Shares
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ascentage Pharma Group International - American Depository Shares
133Total events
8Upcoming
21Tier-1 (high impact)
2024 to 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 50
▲Poster PresentationOlverembatinibFiledPresentation
Updated results of POLARIS-1 Part 1: olverembatinib combined with low-intensity chemotherapy in newly diagnosed Ph+ ALL
Philadelphia chromosome-positive acute lymphoblastic leukemiasource ↗
▲Poster PresentationLisaftoclaxApprovedPresentation
Correlation of baseline characteristics with prognosis in CLL/SLL patients treated with lisaftoclax in pivotal Phase 2 study
chronic lymphocytic leukemia/small lymphocytic lymphomasource ↗
◆Poster PresentationOlverembatinibFiledPresentation
Efficacy of Olverembatinib in CP-CML with prior resistance to ponatinib or asciminib and ASXL1 mutations
Chronic-phase chronic myeloid leukemia (CP-CML) with prior resistance to ponatinib or asciminib and ASXL1 mutationssource ↗
◆Poster PresentationLisaftoclaxApprovedPresentation
Correlation of baseline characteristics with prognosis in CLL/SLL patients treated with Lisaftoclax in a pivotal Phase 2 study
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)source ↗
◆Poster PresentationOlverembatinibFiledPresentation
Safety and preliminary efficacy of Olverembatinib combined with Lisaftoclax in pediatric R/R Ph+ ALL: results of a Phase 1b study
Relapsed/refractory Ph+ ALL (pediatric)source ↗
◆Poster PresentationOlverembatinibFiledPresentation
Updated clinical and translational results of Olverembatinib in SDH-deficient tumors
succinate dehydrogenase (SDH)-deficient tumorssource ↗
◆Poster PresentationLisaftoclaxApprovedPresentation
Global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax in CLL/SLL: GLORA trial in progress
previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)source ↗
▲Oral PresentationOlverembatinibFiledPresentation
Rapid oral presentation of Phase Ib data for olverembatinib + blinatumomab in CML-LBP and Ph+ BCP-ALL at ASCO 2026
lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)source ↗
▲Oral PresentationAPG-115Presentation
First dataset of alrizomadlin (APG-115) as monotherapy or in combination with lisaftoclax in pediatric solid tumors presented at ASCO 2026
pediatric solid tumors (rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, other soft-tissue sarcomas)source ↗
◆Oral PresentationOlverembatinibFiledPresentation
Olverembatinib combined with blinatumomab in CML-LBP or Ph+ BCP-ALL
lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)source ↗
◆Oral PresentationAPG-115Presentation
Alrizomadlin alone or in combination with lisaftoclax for pediatric RMS/STS
relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)source ↗
●AbstractPresentation
Six abstracts from Ascentage Pharma clinical studies selected for ASCO 2026 made available on ASCO website
◆Oral PresentationPresentation
Management to participate in three upcoming investor conferences with webcast availability
▲Other Regulator MilestoneAPG-115Ex-US Regulatory
Alrizomadlin included in CDE's SPARK Plan for pediatric solid tumors
pediatric solid tumors (neuroblastoma, rhabdomyosarcoma, Ewing sarcoma)source ↗
◆Poster PresentationOlverembatinibFiledPresentation
Poster presentation: Olverembatinib efficacy and synergy with chemotherapy in preclinical EC models
endometrial carcinomasource ↗
◆Poster PresentationAPG-5918Presentation
Poster presentation: EED inhibitor APG-5918 synergizes with topoisomerase I inhibitors in SCLC models
small-cell lung cancersource ↗
◆Poster PresentationAPG-2449Presentation
Poster presentation: FAK inhibition by APG-2449 enhances MAPK blockade in BRAF V600E models
BRAF V600E-mutant tumorssource ↗
●Poster PresentationOlverembatinibFiledPresentation
Poster presentation on Olverembatinib in endometrial carcinoma preclinical models at AACR 2026
endometrial carcinomasource ↗
●Poster PresentationAPG-2449Presentation
Poster presentation on APG-2449 in BRAF V600E-mutant tumor models at AACR 2026
BRAF V600E-mutant tumors (melanoma, CRC)source ↗
●Poster PresentationAPG-5918Presentation
Poster presentation on APG-5918 in SCLC preclinical models at AACR 2026
small-cell lung cancersource ↗
◆Oral PresentationPresentation
Chinese (Mandarin) investor event with conference call and webcast
◆Oral PresentationPresentation
Management to participate in three upcoming investor conferences with webcast
◆Oral PresentationPresentation
Ascentage Pharma management to participate in fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026
▲IND ClearanceAPG-3288IND
IND clearance by China CDE for APG-3288
relapsed/refractory hematologic malignanciessource ↗
●Oral PresentationPresentation
Corporate presentation at 44th Annual J.P. Morgan Healthcare Conference
▲IND ClearanceAPG-3288IND
FDA IND clearance for BTK degrader APG-3288
relapsed/refractory B-cell malignanciessource ↗
▲IND ClearanceAPG-3288IND
IND clearance by U.S. FDA for APG-3288
relapsed/refractory hematologic malignanciessource ↗
▲Quarterly UpdateLisaftoclaxApprovedCorporate
Inclusion in NRDL coverage of Lisaftoclax in China
●Management ChangeCorporate
Appointment of Dr. David Sidransky as Lead Independent Non-Executive Director
◆Poster PresentationOlverembatinibFiledPresentation
Poster presentation of 4-year follow-up data from registrational Phase 2 trial at ASH 2025
tyrosine kinase inhibitor-resistant chronic-phase chronic myeloid leukemiasource ↗
◆Poster PresentationLisaftoclaxApprovedPresentation
Poster presentation of lisaftoclax plus azacitidine in ND or prior venetoclax-exposed myeloid malignancies at ASH 2025
newly diagnosed or prior venetoclax-exposed myeloid malignanciessource ↗
◆Oral PresentationLisaftoclaxApprovedPresentation
Oral presentation of registrational Phase II study results for lisaftoclax monotherapy in R/R CLL/SLL at ASH 2025
relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomasource ↗
◆Poster PresentationOlverembatinibFiledPresentation
Poster presentation of POLARIS-1 results at ASH 2025
newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemiasource ↗
◆Poster PresentationAPG-5918Presentation
Poster presentation of APG-5918 preclinical data at ASH 2025
multiple myelomasource ↗
▲IND ClearanceOlverembatinibFiledIND
FDA clearance to conduct global registrational Phase III study POLARIS-1 of olverembatinib in Ph+ ALL
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)source ↗
▲EU MAA SubmissionOlverembatinibFiledEx-US Regulatory
EMA clearance to conduct global registrational Phase III study POLARIS-1 of olverembatinib in Ph+ ALL
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)source ↗
◆Oral PresentationPresentation
Management to participate in three investor conferences in December 2025
◆Oral PresentationOlverembatinibFiledPresentation
First dataset from POLARIS-1 to be released at 2025 ASH Annual Meeting
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)source ↗
▲AbstractOlverembatinibFiledPresentation
ASH 2025 abstract data disclosed showing MRD negativity rate and molecular MRD-negative CR rate ~65%
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)source ↗
▲PublicationOlverembatinibFiledPresentation
Publication of Phase Ib safety, efficacy and novel mechanism data in SDH-deficient GIST in Signal Transduction and Targeted Therapy
gastrointestinal stromal tumors (GIST)source ↗
◆Oral PresentationPresentation
Management participation in investor conferences in November 2025
◆Oral PresentationPresentation
Management to participate in three investor conferences in October 2025
◆Oral PresentationPresentation
Management to participate in three investor conferences in September 2025
Past FDA Catalysts and PDUFA Decisions
How AAPG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-13 | Lisaftoclax (APG-2575) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C51 / 100
Pipeline Score
$952M
Pipeline Value
Overvalued
Valuation Signal
10
Drugs Scored
0.7x
rNPV / MCap
Top 16%
Micro Cap(rank 106 of 658)
Percentile Rank
Ascentage Pharma Group International - American Depository Shares carries a moderate pipeline score (51/100), with $2.9B risk-adjusted pipeline value, led by APG-115 in T-Prolymphocytic Leukemia (Phase 2), across $136B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| APG-115 Small moleculeNCT04496349 | T-Prolymphocytic Leukemia | Phase 2 | RECRUITING | 78 | May 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every AAPG program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| olverembatinib | chronic myeloid leukemia | Phase 3 | 2026-06-14 | deep and durable responses in patients with chronic-phase CML (CML-CP) without the T315I mutationRead More | Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 CongressRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zhai YifanOfficer (Chief Medical Officer) | Option | 95,575 1,193,569 held | $0.00 | 05/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AAPG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in AAPG for Q2 2026. | ||||
AAPG Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AAPG ranks across every disease it competes in
Competitive Position is a premium feature
See how AAPG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAAPG News
AAPGAscentage Pharma to Participate in Four Upcoming Investor Conferences
Ascentage Pharma Group International will participate in four upcoming investor conferences in New York, showcasing its innovative therapies and recent product approvals. The conferences include presentations and one-on-one meetings, allowing investors to engage with the company's management. Ascentage continues to develop therapies targeting unmet medical needs in cancer, bolstered by a strong pipeline and strategic partnerships.
Read more →AAPGAscentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Ascentage Pharma reported a 29% increase in revenue for the first half of 2026, reaching $44.5 million, driven by product sales. The company has expanded its leadership team and is currently conducting nine registrational Phase III clinical trials, with notable progress in its key products, Olverembatinib and Lisaftoclax. Despite these positive developments, the company reported a significant loss of $120.4 million during the same period.
Read more →AAPGAscentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
Ascentage Pharma will participate in the Evercore 2nd Annual China Biotech Summit from August 17-19, 2026. The company's management will engage in a fireside chat and one-on-one investor meetings during the event. Ascentage Pharma is recognized for its innovative therapies targeting cancer, including its approved products and ongoing clinical trials.
Read more →AAPGAscentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
Ascentage Pharma Group International will announce its six-month interim results for 2026 on August 19, 2026. The company will host investor webcasts in both Mandarin and English to discuss these results and provide business updates. Ascentage Pharma is recognized for its innovative cancer therapies and has multiple ongoing Phase III trials.
Read more →AAPGAscentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Ascentage Pharma has appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer. These appointments aim to enhance the company's global business development and commercialization efforts, particularly in the oncology sector. Both executives bring extensive experience in their respective fields, which aligns with Ascentage's strategy to expand its global footprint and advance its innovative therapies.
Read more →AAPGAscentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, has been named No. 3 in The Medicine Maker Power List 2026 for his contributions to oncology and drug development. The recognition highlights his leadership in advancing innovative cancer therapies, including olverembatinib and lisaftoclax. Ascentage Pharma continues to progress with multiple global Phase III trials, addressing significant unmet medical needs in cancer treatment.
Read more →AAPGAscentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, showcasing the efficacy of olverembatinib and lisaftoclax in treating hematologic malignancies. Olverembatinib demonstrated significant responses in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Lisaftoclax showed promising results in pediatric patients with relapsed/refractory conditions. These findings support the ongoing development of these therapies.
Read more →AAPGHong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly d
Ascentage Pharma Group International announced a voluntary share purchase by the Trustee for the 2022 RSU Scheme. On June 11, 2026, the Trustee acquired 110,000 existing shares for a total consideration of HK$3,671,094, representing approximately 0.0294% of the total issued shares. This purchase aims to fulfill the company's obligations related to the RSUs upon their vesting. No new grants have been made under the RSU Scheme aside from initial awards since June 2022, indicating a steady approach to equity compensation.
Read more →AAPGAscentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma presented promising data on olverembatinib combined with blinatumomab at the 2026 ASCO Annual Meeting. The Phase Ib study showed high response rates in patients with relapsed/refractory Ph+ BCP-ALL and CML-LBP. The combination therapy was well tolerated, indicating its potential as a novel treatment strategy for these challenging hematologic malignancies.
Read more →AAPGAscentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
Ascentage Pharma presented its first dataset on alrizomadlin (APG-115), an MDM2-p53 inhibitor, at the 2026 ASCO Annual Meeting. The data showed promising antitumor activity in pediatric patients with relapsed/metastatic rhabdomyosarcoma and other soft-tissue sarcomas. Alrizomadlin demonstrated a favorable safety profile and was included in China's SPARK Plan for further development in pediatric oncology.
Read more →AAPGAscentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
Ascentage Pharma presented updated clinical data for olverembatinib as a second-line therapy for chronic-phase chronic myeloid leukemia (CML-CP) at the 2026 ASCO Annual Meeting. The study reported a complete cytogenetic response rate of 91.3% and a major molecular response rate of 60.9% after 24 cycles of treatment. The drug demonstrated a manageable safety profile, with no new safety signals identified, reinforcing its potential in treating patients who failed first-line therapy.
Read more →AAPGAscentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
Ascentage Pharma announced the presentation of six abstracts at the 2026 ASCO Annual Meeting, showcasing data from ongoing studies of its lead drug candidates. Notably, olverembatinib demonstrated high response rates in patients with chronic myeloid leukemia and other hematological malignancies. The meeting will occur from May 29 to June 2, 2026, in Chicago, IL.
Read more →AAPGAscentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
Ascentage Pharma announced that it will present 17 clinical advances at the upcoming EHA2026 Congress in Stockholm, Sweden. The presentations will include key data on Olverembatinib and Lisaftoclax, two innovative therapies for hematologic malignancies. This event is a major platform for sharing research advancements in hematology.
Read more →AAPGAscentage Pharma to Participate in Three Upcoming Investor Conferences ROCKVILLE, MD. and
Ascentage Pharma Group International announced its participation in three upcoming investor conferences, indicating active engagement with investors. The company continues to focus on developing novel therapies for unmet medical needs in oncology, notably through its robust pipeline which includes approved drugs and ongoing Phase III trials. Ascentage Pharma leverages strategic partnerships with major biotech and pharmaceutical firms to enhance its research and development efforts.
Read more →AAPGHong Kong Exchanges and Clearing
Ascentage Pharma Group International has announced its Annual General Meeting (AGM) to take place on May 20, 2026, at its facility in Suzhou, Jiangsu, China. The notice includes details about resolutions related to share allotments and repurchases, which will require the approval of shareholders. The notice underscores the company's compliance with regulations and procedures regarding shareholder meetings and mandates. The Board of Directors is led by Dr. Yang Dajun, with various members listed in the announcement.
Read more →AAPGAscentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
Ascentage Pharma announced the selection of six abstracts for presentation at the 2026 ASCO Annual Meeting, including three rapid oral presentations. The data will focus on their key drug candidates: Olverembatinib, Lisaftoclax, and Alrizomadlin. This marks the company's ninth consecutive year at ASCO, emphasizing its commitment to advancing cancer therapies.
Read more →AAPGAscentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
Ascentage Pharma announced the presentation of four preclinical studies at the AACR 2026 Annual Meeting, showcasing the potential of their drug candidates, including Olverembatinib, APG-2449, and APG-5918. These studies explore innovative combination therapies for various cancers, indicating the company's commitment to addressing unmet medical needs. The research highlights new applications and strategic focuses in cancer treatment.
Read more →About Ascentage Pharma Group International - American Depository Shares
BIOPHARMAWATCH ELITE PLUS
Trade the next AAPG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime